Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

8.910 -0.190 (-2.09%)
Streaming Delayed Price Updated: 11:32 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast ↗
4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70. 
Via Benzinga
News headline image
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Is 4D Molecular (FDMT) Stock Up 85% Today? ↗
Investors in 4D Molecular Therapeutics and FDMT stock are seeing big gains today, as the stock surges 80% on positive trial results. 
Via InvestorPlace
News headline image
Crude Oil Moves Higher; Caterpillar Posts Upbeat Earnings ↗
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Monday. The Dow traded down 0.53% to 38,450.28 while the NASDAQ fell 0.11% to 15,612.52. The... 
Via Benzinga
Topics Stocks
News headline image
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Gold Moves Lower; ISM Services PMI Beats Estimates ↗
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. The Dow traded down 1.04% to 38,253.72 while the NASDAQ fell 0.86% to 15,493.97. The... 
Via Benzinga
Topics Stocks
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today? ↗
4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity. 
Via Benzinga
News headline image
Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
Dow Tumbles 150 Points; McDonald's Sales Miss Views ↗
U.S. stocks traded lower this morning, with the Dow Jones index falling around 150 points on Monday. Following the market opening Monday, the Dow traded down 0.41% to 38,494.03 while the NASDAQ fell... 
Via Benzinga
Topics Earnings Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket ↗
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning! 
Via InvestorPlace
News headline image
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
News headline image
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Abbott Laboratories, Nasdaq, Spirit AeroSystems And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.